

Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Versi 7.0	on	Revision Date: 06.07.2024		S Number: 737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016		
	FION 1 : Product	IDENTIFICATION	:	Mometasone / Po mulation	osaconazole / Gentamicin / Polymyxin B For-		
I	Manufa	cturer or supplier's d	letai	ls			
(Company		:	Intervet Australia Pty Limited (trading as MSD Animal He			
1	Addres	5	:	91-105 Harpin St Bendigo 3550, V			
-	Telepho	one	:	1 800 033 461			
E	Emerge	ency telephone number	· :	Poisons Informat	ion Centre: Phone 13 11 26		
E	E-mail a	address	:	EHSDATASTEW	ARD@msd.com		
F	Recom	mended use of the ch	nem	ical and restrictio	ons on use		
		mended use ions on use	:	Veterinary produce Not applicable	ct		

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification		
Reproductive toxicity	:	Category 1A
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Kidney, inner ear)
GHS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360D May damage the unborn child. H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure if swallowed.
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapours.



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
7.0	06.07.2024	772737-00020	Date of first issue: 23.06.2016

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Gentamicin	1403-66-3	>= 1 -< 10
Posaconazole	171228-49-2	< 1
Mometasone	83919-23-7	< 0.3
3-Mercaptopropane-1,2-diol	96-27-5	< 1

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.



Version 7.0	Revision Date: 06.07.2024		OS Number: 2737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016			
Prote	Protection of first-aiders		First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).				
Notes	s to physician	:		ically and supportively.			
SECTION	5. FIREFIGHTING MEA	SU	RES				
Suita	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (Dry chemical				
	Unsuitable extinguishing media Specific hazards during fire- fighting		None known.				
•			Exposure to com	bustion products may be a hazard to health.			
Haza ucts	rdous combustion prod-	:	Carbon oxides				
Spec ods	ific extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to d			
for fir	ial protective equipment efighters hem Code	:	In the event of fire	e, wear self-contained breathing apparatus. tective equipment.			
SECTION	6. ACCIDENTAL RELE	AS	E MEASURES				
	onal precautions, protec- equipment and emer-	:		tective equipment. ling advice (see section 7) and personal pro-			

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 7.0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016			
		employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regardin certain local or national requirements.				
SECTION	7. HANDLING AND ST	ORAGE				
Tech	nical measures		ing measures under EXPOSURE PERSONAL PROTECTION section.			
Loca	l/Total ventilation		entilation is unavailable, use with local exhaust			
Advic	e on safe handling	: Do not get on Do not breath Do not swallo Avoid contact Wash skin the Handle in acc practice, base sessment Keep contain Do not eat, di				
Hygie	ene measures	flushing syste place. When using o Wash contam The effective engineering o appropriate d industrial hyg	o chemical is likely during typical use, provide eye ems and safety showers close to the working lo not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, iene monitoring, medical surveillance and the strative controls.			
Cond	litions for safe storage	: Keep in prope Store locked Keep tightly c	erly labelled containers. up. losed.			
Mate	rials to avoid		rdance with the particular national regulations. with the following product types: ng agents			

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
7.0	06.07.2024	772737-00020	Date of first issue: 23.06.2016

ll i i i i i i i i i i i i i i i i i i	Further information: OTO					
Posaconazole	171228-49-2	TWA	300 µg/m3 (OEB 2)	Internal		
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal		
	Further inform	ation: Skin		·		
		Wipe limit	10 µg/100 cm ²	Internal		
Engineering measures	design and op protect produ Essentially no Use closed p If handled in a cabinet, fume tial exists for	All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the poten- tial exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.				
Personal protective equipme	ent					
Respiratory protection Filter type Hand protection	sure assessm ommended g	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Combined particulates and organic vapour type				
Material	: Chemical-res	istant gloves				
Remarks Eye protection Skin and body protection	If the work en mists or aeros Wear a faces potential for o aerosols. : Work uniform Additional boo task being pe posable suits	plasses with signal vironment or a sols, wear the hield or other f lirect contact to or laboratory dy garments sl rformed (e.g.,) to avoid expo ate degowning	de shields or goggles. activity involves dusty c appropriate goggles. ull face protection if the o the face with dusts, n coat. hould be used based u sleevelets, apron, gau used skin surfaces. techniques to remove	ere is a hists, or pon the htlets, dis-		

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
7.0	06.07.2024	772737-00020	Date of first issue: 23.06.2016

I	Melting point/freezing point	:	No data available
	Initial boiling point and boiling range	:	No data available
I	Flash point	:	No data available
I	Evaporation rate	:	No data available
I	Flammability (solid, gas)	:	Not applicable
I	Flammability (liquids)	:	No data available
	Upper explosion limit / Upper flammability limit	:	No data available
	Lower explosion limit / Lower flammability limit	:	No data available
v	Vapour pressure	:	No data available
I	Relative vapour density	:	No data available
I	Relative density	:	No data available
I	Density	:	No data available
:	Solubility(ies) Water solubility	:	No data available
	Partition coefficient: n- octanol/water	:	Not applicable
	Auto-ignition temperature	:	No data available
I	Decomposition temperature	:	No data available
Ň	Viscosity Viscosity, kinematic	:	No data available
I	Explosive properties	:	Not explosive
(Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
I	Molecular weight	:	No data available
	Particle characteristics Particle size	:	Not applicable



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
7.0	06.07.2024	772737-00020	Date of first issue: 23.06.2016

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products	:	None known. Oxidizing agents No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation
	Skin contact
	Ingestion
	Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg
		Method: Calculation method

Components:

Gentamicin:

I	Acute oral toxicity	:	LD50 (Rat): 8,000 - 10,000 mg/kg
			LD50 (Mouse): 10,000 mg/kg
	Acute inhalation toxicity	:	LC50 (Rat): > 0.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.
	Acute toxicity (other routes of administration)	:	LD50 (Rat): 67 - 96 mg/kg Application Route: Intravenous
			LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular
			LDLo (Monkey): 30 mg/kg Application Route: Intravenous
-	Posaconazole:		
	Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
I			$ DFO(Merror) = 2.000 \mathrm{mg}//\mathrm{cg}$



Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version 7.0	Revision Date: 06.07.2024		9S Number: 2737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
Ac	ute dermal toxicity	:	LD50 (Rat): > 2,00	00 mg/kg
Mo	ometasone:			
Ac	ute oral toxicity	:	LD50 (Rat): > 2,00)0 mg/kg
			LD50 (Mouse): > 2	2,000 mg/kg
Ac	ute inhalation toxicity	:	LC50 (Rat): > 3.3 Exposure time: 4 h Test atmosphere: Remarks: No mort	י ר
			LC50 (Mouse): > 3 Exposure time: 4 h Test atmosphere:	1
	ute toxicity (other routes of ministration)	:	LD50 (Rat): 300 m Application Route: Symptoms: Breath	Subcutaneous
	Mercaptopropane-1,2-diol			
Ac	ute oral toxicity	:	LD50 (Rat): 648 m	ng/kg
Ac	ute dermal toxicity	:	LD50 (Rabbit): 673	3 mg/kg
	in corrosion/irritation ot classified based on availa	hla	information	
	omponents:	DIE		
Ge	entamicin:			
	ecies	:	Rabbit Mild skin irritation	
Po	saconazole:			
Sp Re	ecies sult	:	Rabbit No skin irritation	
Мс	ometasone:			
Sp Re	ecies esult	:	Rabbit No skin irritation	
	Mercaptopropane-1,2-diol: ecies	:	Rabbit	
Re	esult	:	Skin irritation	



ersion .0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
	us eye damage/eye lassified based on av		
Com	ponents:		
Genta	amicin:		
Speci Resu		: Rabbit : Mild eye irritat	ion
Posa	conazole:		
Speci Resu		: Rabbit : Mild eye irritat	ion
Mom	etasone:		
Speci Resu	ies It	: Rabbit : No eye irritatio	on
3-Mei	rcaptopropane-1,2-c	liol:	
Speci Resu		: Rabbit : Irritation to ey	es, reversing within 21 days
Resp	iratory or skin sens	itisation	
Skin	sensitisation		
Not c	lassified based on av	ailable information.	
	iratory sensitisatior lassified based on av		
Com	ponents:		
Genta	amicin:		
Rema	arks	: No data availa	ble
Posa	conazole:		
Test	Гуре	: Magnusson-K	ligman-Test
Expos Speci	sure routes ies	: Skin contact : Guinea pig	
Resu		: negative	
Mom	etasone:		
Test		: Maximisation	Test
Expos Speci	sure routes	: Dermal : Guinea pig	
	ssment		e skin sensitisation.
Resu	lt	: negative	
Rema	arks	: The results of	a test on guinea pigs showed this substand

- : negative
 - : The results of a test on guinea pigs showed this substance to



ersion .0	Revision Date: 06.07.2024	SDS Numl 772737-00	
II		be a w	eak skin sensitiser.
3-Me	rcaptopropane-1,2-0	diol:	
Test Expos Speci Metho Resu	Type sure routes ies od It	: Local l : Skin co : Mouse	Test Guideline 429
Asses	ssment		pility or evidence of low to moderate skin sensitisation humans
Chro	nic toxicity		
Not c	n cell mutagenicity lassified based on av ponents:	ailable informa	tion.
	amicin:		
Geno	toxicity in vitro		ype: In vitro mammalian cell gene mutation test : negative
			ype: Chromosome aberration test in vitro : equivocal
	toxicity in vivo	cytoge Specie Applica	ype: Mammalian erythrocyte micronucleus test (in vivo netic assay) es: Mouse ation Route: Intravenous injection : negative
II Posa	conazole:		
	toxicity in vitro		ype: Bacterial reverse mutation assay (AMES) : negative
			ype: Chromosomal aberration : negative
Geno	toxicity in vivo	Specie Cell typ Applica	ype: Micronucleus test es: Mouse pe: Bone marrow ation Route: Intravenous : negative
Mom	etasone:		
	toxicity in vitro		ype: Bacterial reverse mutation assay (AMES) : negative



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

ersion)	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
	toxicity in vivo	Test Type: Test syster Result: neg Test Type: Test syster Result: pos Test Type: Result: neg : Test Type: Species: N Application Result: neg Test Type: Species: R Cell type: E Result: neg Test Type: Species: R Cell type: L	Chromosomal aberration n: Chinese hamster lung cells jative Chromosomal aberration n: Chinese hamster ovary cells itive Mouse Lymphoma jative Micronucleus test ouse Route: Oral jative Chromosomal aberration at Sone marrow jative unscheduled DNA synthesis assay at iver cells
	cell mutagenicity -	Result: nec : Weight of e cell mutage	evidence does not support classification as a gern
	captopropane-1,2-di	: Test Type: Method: O Result: neg Remarks: I Test Type:	Bacterial reverse mutation assay (AMES) ECD Test Guideline 471 gative Based on data from similar materials In vitro mammalian cell gene mutation test ECD Test Guideline 476
		Result: neg Remarks: I Test Type: Method: O Result: neg	jative Based on data from similar materials Chromosome aberration test in vitro ECD Test Guideline 473

Carcinogenicity

Not classified based on available information.



ersion 0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
Comr	oonents:		
	amicin: nogenicity - Assess-	: No data availa	ble
ment	logenicity - Assess-	. No uata avalla	
Posa	conazole:		
Speci		: Rat	
	ation Route	: oral (feed)	
	sure time	: 2 Years	
Resul		: positive	
Rema	rks	: The mechanisi	m or mode of action is not relevant in humans
Speci		: Mouse	
Applic	ation Route	: Oral	
	sure time	: 2 Years	
Resul		: positive	
Rema	rks	: The mechanisi	m or mode of action is not relevant in humans
Mome	etasone:		
Speci	es.	: Rat	
	ation Route	: Inhalation	
	sure time	: 2 Years	
Dose		: 0.067 mg/kg b	odv weight
Resul	t	: negative	, ,
Speci	es	: Mouse	
	ation Route	: Inhalation	
	sure time	: 19 Months	
Dose		: 0.160 mg/kg b	ody weight
Resul	t	: negative	
Renro	oductive toxicity		
-	lamage the unborn chi	Id	
-	-	iu.	
Comp	oonents:		
	amicin:	- -	
Effect	s on fertility		o-generation reproduction toxicity study
		Species: Rat	1.20 mg/kg hadu waight
			L: 20 mg/kg body weight hificant adverse effects were reported
		Result: NO SIGI	inicant auverse effects were reported
Effect	s on foetal develop-	: Test Type: Em	bryo-foetal development
ment		Species: Rabb	
		Developmenta	I Toxicity: NOAEL: 3.6 mg/kg body weight bryo-foetal toxicity
1			bryo-foetal development
		Lact Luna Lm	



rsion	Revision Date: 06.07.2024	SDS Numbe 772737-000	
		Develop	ion Route: Intraperitoneal mental Toxicity: LOAEL: 75 mg/kg body weight Embryo-foetal toxicity
		Test Typ Species Applicat Develop	be: Embryo-foetal development
		Species Applicat Develop	pe: Embryo-foetal development : Rat ion Route: Intraperitoneal mental Toxicity: LOAEL: 50 mg/kg body weight oetal mortality, No malformations were observed.
Repro sessn	oductive toxicity - As- nent		evidence of adverse effects on development from epidemiological studies.
Posa	conazole:		
Effect	s on fertility	Species General	be: Fertility/early embryonic development : Rat, male Toxicity - Parent: NOAEL: 180 mg/kg body weight ms: No effects on mating performance negative
		Species General	be: Fertility/early embryonic development : Rat, female Toxicity - Parent: NOAEL: 45 mg/kg body weight ns: No effects on mating performance negative
Effect ment	s on foetal develop-	Species Applicat Develop	be: Embryo-foetal development : Rat, female ion Route: Oral mental Toxicity: LOAEL: 29 mg/kg body weight Fetotoxicity, Malformations were observed.
		Species Develop	be: Embryo-foetal development : Rabbit, female mental Toxicity: LOAEL: 40 mg/kg body weight Fetotoxicity
Repro sessn	oductive toxicity - As- nent		vidence of adverse effects on development, based o experiments.
Mom	etasone:		
	s on fertility	: Test Typ Species	be: Fertility : Rat



rsion)	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
		Fertility: NOA Symptoms: F weight	Route: Subcutaneous AEL: 0.015 mg/kg body weight Reduced embryonic survival, Reduced foetal ffects on fertility, Effect on reproduction capacity
Effect ment	s on foetal develop-	Species: Mo Application F Embryo-foeta	mbryo-foetal development use Route: Subcutaneous al toxicity: LOAEL: 0.06 mg/kg body weight ryotoxic effects., Teratogenicity and developmen-
		Species: Rat Application F Embryo-foeta	mbryo-foetal development Route: Dermal al toxicity: LOAEL: 0.3 mg/kg body weight ryo-foetal toxicity
		Species: Rat Application F Embryo-foeta	mbryo-foetal development obit Route: Dermal al toxicity: LOAEL: 0.15 mg/kg body weight ryo-foetal toxicity, Malformations were observed.
		Species: Rat Application F Embryo-foeta	mbryo-foetal development Route: Subcutaneous al toxicity: LOAEL: 0.15 mg/kg body weight ts on newborn
		Species: Rat Application F Embryo-foeta	
Repro sessn	oductive toxicity - As- nent	animal exper	ce of adverse effects on development, based on iments., Some evidence of adverse effects on on and fertility, based on animal experiments.
3-Mer	captopropane-1,2-did	ol:	
	s on fertility	: Test Type: T Species: Rat Application F Method: OE0 Result: nega	Route: Ingestion CD Test Guideline 416
Effect	s on foetal develop-	: Test Type: E	mbryo-foetal development



Version 7.0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
ment		Result: negativ) Test Guideline 414
	Γ - single exposure lassified based on ava	ailable information.	
Com	ponents:		
	etasone:		
Rema	arks	: Based on avail	able data, the classification criteria are not met.
May o swallo	F - repeated exposur cause damage to orga owed. ponents:		through prolonged or repeated exposure if
	amicin:		
Targe	et Organs ssment	: Kidney, inner e : Causes damag exposure.	ear ge to organs through prolonged or repeated
Posa	conazole:		
Targe	sure routes et Organs ssment	organs, Nervou	Bone marrow, Kidney, Liver, Reproductive us system ge to organs through prolonged or repeated
Mom	etasone:		
Expo Targe	sure routes et Organs ssment		t/mist/fume) n, Liver, Kidney, Skin nage to organs through prolonged or repeated
Repe	ated dose toxicity		
Com	ponents:		
Gent	amicin:		
		: Dog : 3 mg/kg : Intramuscular : 12 Months	



Version 7.0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016		
Targe Symp	et Organs otoms	: Kidney : Vomiting, Sa	livation		
Expo	EL cation Route sure time et Organs ies	 Monkey 50 mg/kg Subcutaneous 3 Weeks Kidney, inner ear Monkey 			
Appli Expo	cation Route sure time et Organs	: 6 mg/kg : Intramuscula : 3 Weeks : Blood, Kidne	r y, inner ear, Liver		
Expo	EL	: Rat : 5 mg/kg : 10 mg/kg : Intramuscula : 52 Weeks : Kidney, Bloo			
Expo	EL	: Rat : 12.5 mg/kg : 50 mg/kg : Intramuscula : 13 Weeks : Kidney	r		
Spec LOAE Appli Expo		: Rat, female : 5 mg/kg : Oral : 6 Months : Adrenal glan	d, Lungs, Heart, Liver, spleen, Kidney, Ovary		
Expo		: Dog : 3 mg/kg : Oral : 392 Days : Lungs, Liver, cord, lympho	Brain, small intestine, Adrenal gland, Spinal id tissue		
Expo		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrov	v, Adrenal gland, Lymph nodes, Blood		
Spec	ies	: Dog			



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 7.0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
Expo	EL cation Route sure time et Organs		nd, Bone marrow, Kidney, Nervous system, mus gland, Testis, lymphoid tissue
Expo		: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gas	trointestinal tract, spleen
Expo		: Monkey : 8 mg/kg : Intravenous : 1 Months : Cardio-vase	s cular system, Lungs, Adrenal gland, Blood
Speci NOAI LOAE Applie Expos	EL	: Rat : 0.005 mg/k : 0.3 mg/kg : Oral : 30 d : Lymph nod	g es, Liver, Adrenal gland, Skin, thymus gland
Expo		: Dog : 0.5 mg/kg : Oral : 30 d : Lymph nod	es, Liver, Adrenal gland, Skin, thymus gland
Speci NOAI Applie Expo Targe		: 90 d : Adrenal gla	g/l dust/mist/fume) nd, Lungs, Lymph nodes, spleen, Bone marrow, er, thymus gland
Speci NOAI Applia Expo Targe		: 90 d : Adrenal gla	l dust/mist/fume) nd, Lungs, Lymph nodes, spleen, Bone marrow, mus gland, Liver
3-Me	rcaptopropane-1,2-d	liol:	

Species:RatLOAEL:> 100 mg/kg



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 7.0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
		: Ingestion : 55 Days : OECD Test C : Based on dat	Guideline 422 a from similar materials
Not cl	ation toxicity assified based on avai ponents:	lable information.	
	etasone: pplicable		
Expe	rience with human ex	posure	
Comp	oonents:		
Genta	amicin:		
Inges	tion	: Target Organ Target Organ Symptoms: D deafness	
Posa	conazole:		
Inges	tion		Cough, Headache, Nausea, Vomiting, Fever, Liver , pruritis, Diarrhoea, hypertension, neutropenia, balance
Mome	etasone:		
Inhala	ation	piratory tract	llergic rhinitis, Headache, pharyngitis, upper res- infection, sinusitis, oral candidiasis, Back pain, etal pain, immune system effects, indigestion
Skin o	contact		Permatitis, Itching
Furth	er information		
Comp	oonents:		
Mome Rema	etasone: arks	: Dermal absor	rption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Gentamicin:

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 86 mg/l



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

ersion 0	Revision Date: 06.07.2024		DS Number: 2737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016				
aquati	c invertebrates		Exposure time: 48 h Method: OECD Test Guideline 202					
			LC50 (Americam Exposure time: 90 Method: US-EPA					
Toxici [:] plants	ty to algae/aquatic	:	Exposure time: 72	chneriella subcapitata (green algae)): 10 μg/l 2 h est Guideline 201				
			μg/l Exposure time: 72	rchneriella subcapitata (green algae)): 1.5 2 h est Guideline 201				
			Exposure time: 72	flos-aquae (cyanobacterium)): 4.7 μg/l 2 h est Guideline 201				
			Exposure time: 72	a flos-aquae (cyanobacterium)): 1.6 μg/l 2 h est Guideline 201				
Toxici	ty to microorganisms	:	EC50: 288.7 mg/l Exposure time: 3 Test Type: Respi Method: OECD T	h				
Posad	conazole:							
Toxici	ty to fish	:	Exposure time: 9 Method: OECD T	chus mykiss (rainbow trout)): > 0.95 mg/l 6 h est Guideline 203 city at the limit of solubility				
	ty to daphnia and other c invertebrates	:	Exposure time: 48	nagna (Water flea)): 0.276 mg/l 8 h est Guideline 202				
Toxici [;] plants	ty to algae/aquatic	:	0.509 mg/l Exposure time: 72	chneriella subcapitata (green algae)): > 2 h est Guideline 201				
			mg/l Exposure time: 72	rchneriella subcapitata (green algae)): 0.041 2 h est Guideline 201				

Toxicity to fish (Chronic tox- : NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l



Version 7.0	Revision Date: 06.07.2024		9S Number: 2737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016		
icity)		Exposure time: 33 Method: OECD Te			
aqu	Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)		NOEC (Daphnia magna (Water flea)): 0.244 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility			
Тох	Toxicity to microorganisms		EC50 (Natural microorganism): > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209			
Moi	metasone:					
	icity to fish	:	Exposure time: 96	ryllina (Silverside)): 0.11 mg/l 5 h city at the limit of solubility		
			Exposure time: 7	n variegatus (sheepshead minnow)): > 5 mg/l d city at the limit of solubility		
	icity to daphnia and other atic invertebrates	:	Exposure time: 48 Method: OECD Te			
			EC50 (Americamy Exposure time: 96 Method: US-EPA Remarks: No toxid	3 h		
Tox plar	icity to algae/aquatic nts	:	 EC50 (Pseudokirchneriella subcapitata (green algae)): : mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility 			
Tox icity	icity to fish (Chronic tox-	:	: NOEC (Pimephales promelas (fathead minnow)): 0.000 ⁻⁷ mg/l Exposure time: 32 d Method: OECD Test Guideline 210			
aqu	icity to daphnia and other atic invertebrates (Chron- pxicity)	:	 NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility 			
Тох	icity to microorganisms	:	: EC50: > 1,000 mg/l Exposure time: 3 h			



ersion 0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
		Method: OEC Remarks: No NOEC: 1,000 Exposure time Test Type: Re Method: OEC	
II 3-Me	rcaptopropane-1,2-diol	:	
	ity to fish	: LC50 (Oncorr Exposure time Method: OEC	nynchus mykiss (rainbow trout)): > 10 - 100mg e: 96 h D Test Guideline 203 sed on data from similar materials
	ity to daphnia and other ic invertebrates	Exposure time Method: OEC	ia magna (Water flea)): > 10 - 100 mg/l e: 48 h D Test Guideline 202 sed on data from similar materials
Toxic plants	ity to algae/aquatic	10 - 100 mg/l Exposure time Method: OEC	docelis subcapitata (freshwater green alga)): > e: 72 h D Test Guideline 201 sed on data from similar materials
		mg/l Exposure time Method: OEC	docelis subcapitata (freshwater green alga)): > e: 72 h D Test Guideline 201 sed on data from similar materials
Toxic	ity to microorganisms	Exposure time Method: OEC	ed sludge): > 1 mg/l e: 3 h D Test Guideline 209 sed on data from similar materials
Persi	stence and degradabili	ity	
Com	ponents:		
	amicin: gradability	: Result: rapidly Biodegradatic Exposure time Method: OEC	n: 100 %



Version 7.0	Revision Date: 06.07.2024		S Number: 2737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
Biode	gradability	:	Biodegradation Exposure time	
Stabil	Stability in water			alf life (DT50): > 30 d) Test Guideline 111
Mome	etasone:			
Biode	gradability	:	Biodegradation Exposure time	
Stabil	ity in water	:	Hydrolysis: 50 Method: OECE	%(12 d)) Test Guideline 111
	captopropane-1,2-c	liol		
	gradability	:		/ biodegradable. ed on data from similar materials
Bioac	cumulative potentia	al		
<u>Comp</u>	oonents:			
Genta	amicin:			
	on coefficient: n- ol/water	:	log Pow: < -2	
Posa	conazole:			
Bioac	cumulation	:	Bioconcentratio	mis macrochirus (Bluegill sunfish) on factor (BCF): 20) Test Guideline 305
	on coefficient: n- ol/water	:	log Pow: 4.15	
Mome	etasone:			
Bioac	cumulation	:	Bioconcentratio	mis macrochirus (Bluegill sunfish) on factor (BCF): 107.1) Test Guideline 305
	on coefficient: n- ol/water	:	log Pow: 4.68	
	captopropane-1,2-c			
	on coefficient: n- ol/water	:	log Pow: -0.84 Method: OECE	D Test Guideline 117



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

	Version 7.0	Revision Date: 06.07.2024	SDS Number: 772737-00020	Date of last issue: 06.04.2024 Date of first issue: 23.06.2016
--	----------------	---------------------------	-----------------------------	---

Mobility in soil

Components:

Distribution among environ- mental compartments	:	log Koc: 5.52
Mometasone:		
Distribution among environ- mental compartments	:	log Koc: 4.02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

nan-
•

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG		
UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes
IATA-DGR		
UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Gentamicin, Mometasone)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passen- ger aircraft)	:	964
Environmentally hazardous	:	yes
IMDG-Code		



Mometasone / Posaconazole / Gentamicin / **Polymyxin B Formulation**

Version	Revision Date:	SD	S Number:	Date of last issue: 06.04.2024
7.0	06.07.2024	77	2737-00020	Date of first issue: 23.06.2016
UN n	number	:	UN 3082	
Prop	er shipping name	:	ENVIRONME	NTALLY HAZARDOUS SUBSTANCE, LIQUID,
			N.O.S.	
			(Gentamicin, M	Mometasone)
Class	S	:	9	
Pack	ing group	:	111	
Labe	ls	:	9	

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

F-A, S-F

ves

Not applicable for product as supplied.

National Regulations

EmS Code

Marine pollutant

ADG		
UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
		(Gentamicin, Mometasone)
Class	:	9
Packing group	:	
Labels	:	9
Hazchem Code	:	•3Z
Environmentally hazardous	:	yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons : Schedule 5 (Please use the original publication to check for Standard) Instrument specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements

: There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS	:	not determined

DSL not determined :



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

VersionRevision Date:SDS Number:Date of last issue: 06.04.20247.006.07.2024772737-00020Date of first issue: 23.06.2016

IECSC

: not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION

Further information

Revision Date	:	06.07.2024
Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response: ERG - Emergency Response Guide: GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
7.0	06.07.2024	772737-00020	Date of first issue: 23.06.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN